Skip to main content

Legal wrangling

In light of high-profile pharmaceutical lawsuits in the US, and the recent withdrawal of products such as Vioxx from the market, Guy Anker investigates the implications for the insurance industry

Barely a day goes by without news of a multi-billion-dollar pharmaceutical company facing a class action lawsuit in the US.

While the number of firms facing trial is limited - for the moment - the

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@postonline.co.uk or view our subscription options here: https://subscriptions.postonline.co.uk/subscribe

You are currently unable to copy this content. Please contact info@postonline.co.uk to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Post? View our subscription options

Paul Morden, Munich Re

Paul Morden, CEO of Munich Re UK’s branch is responsible for shaping and delivering reinsurance strategy across the UK and Ireland.

Jason Richards, Swiss Re

As CEO for UK & Ireland at Swiss Re, Jason Richards sits at the centre of one of the most influential reinsurance platforms in the London market, shaping how insurers respond to an increasingly volatile and complex risk environment.

Most read articles loading...

You need to sign in to use this feature. If you don’t have an Insurance Post account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here